A Phase 3 interventional study of ATSN-201 in X-linked Retinoschisis, sponsored by Atsena Therapeutics Inc.. Recruiting at 21 sites in 3 countries. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Atsena Therapeutics Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Retinoschisis with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Retinoschisis · United States.
Among the 10 studies in Retinoschisis with a site in United States, this one is the only one that started in 2023, is the only one in phase 3, and was the 9th registered.
19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.
Browse Retinoschisis studies →3 of the 10 studies in Retinoschisis with a site in United States are open now. Recruiting first, the newest first:
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Foundation Fighting Blindness · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Retinoschisis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 5 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 97 is above the median of 19 across 12 interventional studies indexed under Retinoschisis.
Median enrollment 43 across the 4 interventional studies, 46 across the 6 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 7 most frequent:
Atsena Therapeutics Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Atsena Therapeutics Inc. has 1 study filed under Retinoschisis — fewer than ten, so there is no comparison to draw.
1 of the studies in Retinoschisis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Retinoschisis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS).
The study is designed in three parts: a dose escalation phase (Part A), a dose expansion phase (Part B) and a randomized, controlled phase (Part C).
In Part C of the study, eligible patients who enroll in this study will be randomly assigned to be treated with ATSN-201 or to have no treatment; subjects assigned to ATSN-201 will receive the drug as a one-time subretinal injection of ATSN-201 in one eye or both eyes, depending on whether only one or both eyes meet criteria for treatment. Subjects will have regular assessments for 1 year as part of the Main Study Period and additional assessments over the next 4 years as part of the Extension Study Period.
Some subjects may have all their study visits at a surgery site.
Some subjects may go to one study site (a medical site) to determine eligibility and another study site (a surgery site) to have surgery - including pre-operative care and approximately 1-week of post-operative care per treated eye. After the surgery, they will go back to the other study site (the medical site) to complete the follow-up visits.
Subjects who do not receive treatment as part of the control group can choose to receive ATSN-201 in one or both eyes after the 1-year Main Study Period if eligible. If the subject is not eligible at the Month 12 visit, eligibility may be reassessed at the Month 18 visit.
Part A and B:
Inclusion Criteria:
Exclusion Criteria:
Part C:
Inclusion Criteria:
Note: For patients ineligible for bilateral dosing based on the ocular exclusion criteria, the same eye must meet all ocular inclusion criteria, but none of the ocular exclusion criteria, to be eligible for unilateral dosing.
General All of the following criteria must be met for unilateral or bilateral dosing.
Genetically male patients with clinical diagnosis of XLRS caused by pathogenic or likely pathogenic mutations in RS1 OR Genetically female patients with clinical diagnosis of XLRS caused by biallelic pathogenic or likely pathogenic mutations in RS1.
Ocular At least 1 eye must meet all of the following criteria for both unilateral and bilateral dosing.
Exclusion Criteria:
General None of the following criteria can be met for unilateral or bilateral dosing.
Biological: ATSN-201
Biological: ATSN-201
Biological: ATSN-201
Biological: ATSN-201
Biological: ATSN-201
Biological: ATSN-201
Biological: ATSN-201
AAV.SPR-hGRK1-hRS1syn
Part A (Dose Escalation) and Part B (Dose Expansion): Safety and tolerability as assessed by dose-limiting toxicities and treatment-emergent adverse events
Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs).
Time frame: From baseline to week 52
Part C (Phase 3, Randomized, Controlled) Effect of ATSN-201 on visual function.
Proportion of subjects with improvement ≥ 7dB from baseline in microperimetry across prespecified loci in the study eye.
Time frame: From baseline to week 52
Part A and Part B: Visual acuity as assessed by best-corrected visual acuity
Change in best-corrected visual acuity (BCVA).
Time frame: From baseline to week 52
Part A and Part B: Visual acuity as assessed by low-luminance visual acuity
Change in low-luminance visual acuity (LLVA).
Time frame: From baseline to week 52
Part A and Part B: Visual function as assessed by contrast sensitivity
Change in contrast sensitivity.
Time frame: From baseline to week 52
Part A and Part B: Visual function as assessed by microperimetry
Change in microperimetry.
Time frame: From baseline to week 52
Part A and Part B: Macular structure as assessed by spectral domain optical coherence tomography
Change in spectral domain optical coherence tomography (SD-OCT).
Time frame: From baseline to week 52
Part A and Part B: Macular structure as assessed by fundus autofluorescence
Change in fundus autofluorescence (FAF).
Time frame: From baseline to week 52
Part A and Part B: Subject-reported visual function as assessed by the NEI VFQ-25 in adult subjects
Change in the National Eye Institute's Visual Function Questionnaire 25 (NEI VFQ-25) score for adult subjects with scores from 0 to 100 where a higher score indicates a better outcome.
Time frame: From baseline to week 52
Part A and Part B: Subject-reported visual function as assessed by the CVAQC in pediatric subjects
Change in the Cardiff Visual Ability Questionnaire for Children (CVAQC) score for pediatric subjects with scores from -3.00 to +2.80 where a higher score indicates a worse outcome.
Time frame: From baseline to week 52
Part A and Part B: Subject-reported visual function as assessed by the MRDQ in subjects 13 years of age or greater.
Description: Change in the Michigan Retinal Degeneration Questionnaire (MRDQ) score for subjects 13 years of age or greater.
Time frame: From baseline to week 52
Part C: Macular structure as assessed by spectral domain optical coherence tomography
Change in spectral domain optical coherence tomography (SD-OCT).
Time frame: From baseline to week 52
Part C: Visual acuity as assessed by best-corrected visual acuity or low-luminance visual acuity
Change in best-corrected visual acuity (BCVA) or low luminance visual acuity (LLVA).
Time frame: From baseline to week 52
Part C: Visual acuity as assessed by best-corrected visual acuity as measured by Early Treatment Diabetic Retinopathy Study chart
Change in best-corrected visual acuity (BCVA) as assessed by ETDRS.
Time frame: From baseline to week 52
Part C: Visual acuity as assessed by low luminance visual acuity as measured by Early Treatment Diabetic Retinopathy Study chart
Description: Change in low luminance visual acuity (LLVA) as assessed by ETDRS.
Time frame: From baseline to week 52
Part C: Visual function as assessed by microperimetry
Change in microperimetry for subjects.
Time frame: From baseline to week 52
Part C: Functional vision as assessed by reading speed
Change from baseline in reading speed as measured by MNREAD for subjects 8 years of age and older.
Time frame: From baseline to week 52
Part C: Subject-reported visual function as assessed by the MRDQ in subjects 13 years of age or greater
Change in the Michigan Retinal Degeneration Questionnaire (MRDQ) score for subjects 13 years of age or greater.
Time frame: From baseline to week 52
Part C: Subject-reported visual function as assessed by the CVAQC in pediatric subjects
Change in the Cardiff Visual Ability Questionnaire for Children (CVAQC) score for pediatric subjects ages 5-13 years of age.
Time frame: From baseline to week 52
Part C: Subject perception of change and severity (PGIC/PGIS)
Patient global impression of change and severity (PGIC/PGIS).
Time frame: From baseline to week 52
Part C: Evaluate the safety of ATSN-201
Incidence of treatment emergent adverse events (TEAEs).
Time frame: From baseline to week 52
Part C: To evaluate the quality of life in subjects treated with ATSN-201
Change from Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Health Index score and Visual Analogue Scale (VAS) score at Month 12 for subjects ≥ 12 years of age in the ATSN-201 group vs. controls. Scale 0 (worst health you can imagine) to 100 (best health you can imagine).
Time frame: From baseline to week 52
Part C: To evaluate the quality of life in pediatric patients treated with ATSN-201
Change from Baseline in European Quality of Life 5-Dimension Youth 5-Level (EQ-5D-Y-5L) Health Index score and Visual analogue Scale (VAS) score at Month 12 for subjects ≥ 8 to \< 12 years of age in the ATSN201 group vs. controls. Scale 0 (worst health you can imagine) to 100 (best health you can imagine).
Time frame: From baseline to week 52
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Apr 2028, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atsena Therapeutics Inc.